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Effectiveness of biologic DMARDs in monotherapy
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Quality Management Registry
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SCQM collaborating physicians
Abstract
Objectives. To determine the frequency of use of biologic DMARDs (bDMARDs) in monotherapy, to
describe the baseline characteristics of patients treated with bDMARDs in monotherapy and to compare
the effectiveness of bDMARDs in monotherapy with that of bDMARDs in combination with synthetic
DMARDs (sDMARDs).
Methods. Using data from the Swiss RA (SCQMRA) registry, bDMARD treatment courses (TCs) were
classified either as monotherapy or as combination therapy, depending on the presence of concomitant
sDMARDs. Prescription of bDMARD monotherapy was analysed using logistic regression. bDMARD re-
tention was analysed using KaplanMeier and Cox models with the addition of time-varying covariate
effects. Evolution of the DAS28 over time was analysed with mixed-effects models for longitudinal data.
Results. A total of 4218 TCs on bDMARDs from 3111 patients were included, of which 1136 TCs (27%)
were initiated as monotherapy. bDMARD monotherapy was preferentially prescribed to older, co-morbid
patients with longer disease duration, lower BMI, more active disease and more previous bDMARDs. After
adjusting for potential confounding factors, drug retention was significantly lower in monotherapy [hazard
ratio 1.15 (95% CI: 1.03, 1.30)]. Other factors such as type of bDMARD and calendar year of prescription
were associated with a stronger effect on drug retention. Response to treatment in terms of DAS28
evolution was also slightly but significantly less favourable in monotherapy (P= 0.04).
Conclusion. Our data suggest that bDMARD monotherapy is prescribed to more complex cases and is
significantly less effective than bDMARD therapy in combination with sDMARDs, but to an extent that is
clinically only marginally relevant.
Key words: rheumatoid arthritis, biologic DMARD, monotherapy, combination therapy.
Rheumatology key messages
. Monotherapy with biologic agents is commonly used in patients with RA.
. The use of biologic agents in RA varies according to disease and patient characteristics.
. In RA patients with co-morbidities the use of biologics in monotherapy is a reasonable option.
Introduction
Biologic DMARDs (bDMARDs) have markedly changed
the management and outcome of disease of patients
with RA. Clinical guidelines recommend using bDMARDs
in combination with MTX [or in combination with other
synthetic DMARDs (sDMARDs) when MTX is not toler-
ated]. These recommendations are based on data from
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randomized clinical trials demonstrating that TNF antag-
onists (aTNFs) are more effective when combined with
MTX than in monotherapy [1]. The efficacy of bDMARDs
with modes of action other than aTNFs used in monother-
apy has been less examined. However, recent results sug-
gest that tocilizumab has comparable efficacy in
monotherapy and in combination with MTX [2].
Up to one-third of RA patients are treated with
bDMARDs in monotherapy (according to data from differ-
ent registries in Europe and the USA) [310]. This relatively
high percentage may represent patients in whom
sDMARDs have been discontinued during follow-up due
to adverse events or as a result of low disease activity, but
may also include patients in whom bDMARDs were
started in monotherapy because of previous intolerance
to sDMARDs or co-morbidities.
The objectives of this study were: to determine the fre-
quency of use of bDMARDs in monotherapy at baseline or
during the course of therapy; to describe the baseline
characteristics of patients treated with bDMARDs in
monotherapy; and to compare the effectiveness of
bDMARDs in monotherapy with that of bDMARDs in com-
bination with sDMARDs.
Methods
Patient population
Data from the nationwide Swiss Clinical Quality
Management (SCQM) registry for RA was used for this
study. The SCQM-RA registry is a longitudinal cohort of
RA patients (established in 1997), and it has been
described in detail elsewhere [11, 12]. Inclusion criteria
for the SCQM-RA are a diagnosis of RA by a Board-certi-
fied rheumatologist. Ethical approval for the SCQM-RA
and related studies (including this study) was obtained
from the Swiss Academy of Medical Sciences review
board, and all patients were required to provide written
consent prior to enrolment. At inclusion, disease charac-
teristics, concomitant treatments and co-morbidities were
assessed by the rheumatologists and patients filled out
self-administered questionnaires such as HAQ, SF-12
and EuroQoL. Follow-up assessments were performed
at regular intervals, approximately one to four times a
year (disease activity, anti-rheumatic treatments, side ef-
fects, reasons for discontinuation, co-morbidities, etc.)
and included hand and foot X-rays every 1 or 2 years.
The Swiss Society of Rheumatology recommends the in-
clusion of all the patients treated with bDMARDs. More
than 300 (corresponding to 80%) of Swiss rheumatolo-
gists participate in the SCQM. Patients in SCQM-RA
come from diverse clinical settings, with approximately
50% from private practice, 30% from non-academic cen-
tres and 20% from academic centres. The study popula-
tion can be considered a representative sample of the
Swiss RA population on bDMARDs.
The inclusion and exclusion criteria for this study were:
initiation of a bDMARD and a baseline visit within a time
window of 90 days prior to and up to 16 days after the
start of bDMARD treatment, including information on
DAS28. Exclusion criteria were: missing information on
concomitant sDMARDs and overlapping bDMARD treat-
ment courses (TCs). All TCs with bDMARDs (abatacept,
adalimumab, certolizumab pegol, etanercept, golimumab,
infliximab, rituximab and tocilizumab) fulfilling the above-
mentioned inclusion and exclusion criteria were extracted
from the SCQM-RA database and considered eligible for
the present study.
Exposure of interest
TCs were classified as either monotherapy or combination
therapy, depending on the presence of concomitant
sDMARDs at the start of treatment with a bDMARD. In
addition, each TC was classified according to whether
or not the initial therapy was maintained throughout
follow-up, leading to a categorization of TCs into com-
plete mono- or complete combination therapy, and step-
up (addition of sDMARDs) or step-down (discontinuation
of all sDMARDs) therapy.
Study outcomes
The primary outcome variables were bDMARD retention
(time from start to discontinuation of a bDMARD) and evo-
lution of RA disease activity in terms of DAS28 over time.
For the analysis of bDMARD retention, TCs with rituximab
(difficulties in defining the date of drug discontinuation) or
an immediate loss of follow-up were not included. The
covariates considered were: sex, age, BMI, smoking,
number of previously used bDMARDs, calendar year of
bDMARD treatment initiation, disease duration, seroposi-
tivity (presence of RF or ACPA), DAS28, functional disabil-
ity (HAQ), lung, liver or kidney co-morbidity and type of
bDMARD at baseline.
Statistical analysis
The units of interest in this study were the TCs with a
bDMARD. When considered necessary or reasonable,
we accounted for the presence of multiple TCs per patient
using a random patient effect such as the analysis of
DAS28 evolution. The prescription of initial bDMARD
monotherapy in relation to patient characteristics at base-
line of each TC was analysed using logistic regression
analyses. bDMARD retention was analysed using meth-
ods for right censored time to event data (KaplanMeier
and Cox models), with the addition of time-varying covari-
ate effects (extended Cox models). DAS28 change over
time was graphically displayed using cubic spline smooth-
ing and analysed with mixed-effects models for longitu-
dinal data. DAS28 response in terms of remission (DAS28
<2.6) and low disease activity (LDAS, DAS28 43.2) at 12
and 24 months after the start of bDMARD treatment was
analysed using logistic regression analyses. For about
one-quarter of the TCs (2229%, depending on the ana-
lysis), information for at least one covariate was missing.
We therefore re-analysed our main outcomes based on
multiple imputation of missing covariate data. Full details
on outcome variable and covariate definitions, statistical
methods and software can be found as supplementary
data, Methods section, available at Rheumatology Online.
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Results
Study population
A total of 4218 TCs with bDMARDs from 3111 patients
fulfilling the inclusion and exclusion criteria were present
in the SCQM-RA cohort by the end of July 2013. Of the
3111 patients, 2292 (74%) contributed with one and 819
with two or more TCs. More detailed information on the
inclusion of TCs for the present study can be found in
supplementary Fig. S1, available at Rheumatology Online.
Frequency of initial or secondary bDMARD
monotherapy
Overall, 1136 TCs of the 4218 (27%) were initiated as
monotherapy and 3082 (73%) were initiated with
sDMARD(s) co-therapy. Most combination TCs were
initiated with MTX (75%), followed by LEF (26%). Table 1
presents numbers and percentages of mono- and combin-
ation therapy initiated TCs for each bDMARD. The largest
percentage of TCs initiated in monotherapy (46%) was
observed for certolizumab pegol and the smallest (14%)
for infliximab. In 13% of TCs started in combination therapy
with sDMARD(s), at least one (possibly transient) phase of
monotherapy (step-down) occurred. On the other hand, in
14% of TCs started in monotherapy, at least one phase of
co-therapy with sDMARD(s) (step-up) occurred. The major-
ity of monotherapy TCs occurred as a result of initiating the
biologic treatment in monotherapy, as opposed to discon-
tinuation of sDMARD(s) during follow-up (1136 initial mono-
therapy TCs vs 388 step-down monotherapy TCs, Table 1).
Characteristics of patients who started treatment with
bDMARDs in monotherapy or combination therapy
The baseline characteristics of patients at initiation of the
bDMARD treatment are summarized in Table 2. Several
patient and treatment characteristics as well as year of
treatment initiation and type of bDMARD were associated
with initial monotherapy (Table 2), suggesting that mono-
therapy is more often prescribed to older, co-morbid RA
patients, with a lower BMI, longer disease duration, more
previous bDMARDs and higher disease activity.
Effectiveness of bDMARDs started as monotherapy or
in combination with sDMARDs
Biologic DMARD retention
A total of 3312 of the 4218 TCs (79%) were on bDMARDs
other than rituximab and not lost to follow-up immediately.
Among these, 2453 TCs (74%) had complete information
for all covariates. Discontinuation of bDMARD was
observed in 1545 of the 2453 TCs (63%).
The unadjusted estimates of bDMARD retention curves
for mono- and combination therapy based on 3312 TCs
are shown in Fig. 1. Respective estimates for unadjusted
median retention under initial mono- and combination
therapy were 2.08 years (95% CI 1.90, 2.55) for monother-
apy and 2.30 years (95% CI 2.09, 2.58) for combination
therapy. The estimated unadjusted hazard ratio (HR) for
discontinuation of monotherapy vs combination therapy
was 1.13 (95% CI 1.02, 1.24, P= 0.018).
The adjusted HR for discontinuation of TCs initiated in
mono- vs combination therapy based on 2453 TCs was
1.15 (95% CI 1.03, 1.30, P= 0.018). All covariates except
age, BMI, smoking and co-morbidity were found to sig-
nificantly affect the hazard for bDMARD discontinuation
(Table 3). The covariates with the largest impact were
the type of bDMARD and the year of treatment initiation.
We explored potential interactions between initial co-
therapy and type of bDMARD, between initial co-therapy
and co-morbidity and between bDMARD and smoking,
but none were significant (results not shown). For DAS28
and seropositivity we had evidence for a non-proportional
hazard, that is, an HR that is not constant over time.
TABLE 1 Summary of type of co-therapies based on all 4218 eligible TCs contributed by 3111 patients
TCs, n (%)
Initial
combo, n (%)
Initial
mono, n (%)
Complete
combo, n (%)
Step-down,
n (%)
Complete
mono, n (%)
Step-up,
n (%)
ABA 272 (6a) 192 (71b) 80 (29b) 175 (91c) 17 (9c) 75 (94d) 5 (6d)
ADA 1298 (31a) 967 (74b) 331 (26b) 846 (87c) 121 (13c) 276 (83d) 55 (17d)
CER 48 (1a) 26 (54b) 22 (46b) 24 (92c) 2 (8c) 19 (86d) 3 (14d)
ETA 1193 (28a) 777 (65b) 416 (35b) 648 (83c) 129 (17c) 353 (85d) 63 (15d)
GOL 174 (4a) 145 (83b) 29 (17b) 139 (96c) 6 (4c) 27 (93d) 2 (7d)
INF 651 (15a) 559 (86b) 92 (14b) 515 (92c) 44 (8c) 72 (78d) 20 (22d)
RIT 324 (8a) 249 (77b) 75 (23b) 216 (87c) 33 (13c) 64 (85d) 11 (15d)
TOC 258 (6a) 167 (65b) 91 (35b) 131 (78c) 36 (22c) 86 (95d) 5 (5d)
Total 4218 3082 (73 b) 1136 (27b) 2694 (87c) 388 (13c) 972 (86d) 164 (14d)
Reading example: 31% of all bDMARD TCs were with adalimumab (ADA); 26% of ADA TCs were initiated in monotherapy. The
great majority of TCs initiated in combination therapy or monotherapy remained as such during the entire treatment course
(87% and 86%, respectively). Calculation of percentages (may not add to 100 due to rounding): awith respect to total number
of TCs; bwith respect to number of TCs per bDMARD (or in total); cwith respect to number of initial combination therapies per
bDMARD (or in total); dwith respect to number of initial monotherapies per bDMARD (or in total). bDMARD: biologic DMARD;
TCs: treatment courses; initial combo: initial combination therapy; initial mono: initial monotherapy; complete combo: com-
plete combination therapy; complete mono: complete monotherapy; ABA: abatacept; ADA: adalimumab; CER: certolizumab
pegol; ETA: etanercept; GOL: golimumab; INF: infliximab; RIT: rituximab; TOC: tocilizumab.
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For these two covariates, Table 3 presents more than one
HR estimate to illustrate its behaviour over time.
DAS28 over time
All 4218 TCs were used to investigate the course of
DAS28 over time. A smoothed plot of the raw time
course of DAS28 (Fig. 2) suggests that DAS28 levels
were slightly higher at baseline (0.10.2 U) in monotherapy
than in combination TCs and improved slightly less after
the start of bDMARD treatment. The multiple covariate-
adjusted mixed-effects model, analysing a total of
3280 TCs (78%) with complete covariate information con-
firmed the crude model (supplementary Table S1, avail-
able at Rheumatology Online). Indeed, there was a
significant but small difference in the long-term slope in
favour of combination therapy (P= 0.04) as well as a clear
indication of a difference between therapy types with
respect to the DAS28 time course overall (P= 0.001, like-
lihood ratio test for the joint effect of co-therapy on initial
drop and long-term slope). The estimated difference in
DAS28 between monotherapy and combination TCs
after 1, 2 and 4 years was 0.11, 0.15 and 0.23 DAS28
units, respectively.
Other covariates were also associated with significant
differences in the course of DAS28 over time. A greater
improvement in DAS28 over time in the initial 2 months
was observed in TCs started in more recent calendar
years and in TCs with tocilizumab. On the other hand,
the initial improvement was less pronounced in patients
with longer disease duration, more previous bDMARDs
and on infliximab. Male vs female sex and more previous
bDMARDs were associated with a slightly better long-
term course of DAS28 (supplementary Table S1, available
at Rheumatology Online). The results from a robustness
analysis by excluding TCs with high residuals (in total 2%
of TCs) were similar (data not shown).The results from
the analyses based on multiple imputation of missing
covariates were qualitatively similar to those from the
TABLE 3 Results from extended, covariate-adjusted Cox
proportional hazards analysis of bDMARD retention
(n= 2453 TCs)
HR (95% CI) P-value
Mono- vs combination
therapy
1.15 (1.03, 1.30) 0.018
Age, per 20 years more 0.97 (0.90, 1.06) 0.52
BMI, per 6 kg/m2 more 1.004 (0.94, 1.07) 0.92
No. of previous bDMARDs
1 vs 0 1.24 (1.09, 1.41) 0.0014
2+ vs 0 1.20 (0.997, 1.46) 0.054
Disease duration,
per 10 years more
0.91 (0.85, 0.96) 0.0019
DAS28, per 2 U
more
<1 year since treatment
start
1.27 (1.13, 1.42) <0.0001a
51 year since treatment
start
1.01 (0.91, 1.12) 0.0021b
HAQ, per 1 U more 1.10 (1.02, 1.19) 0.016
Sex, male vs female 0.84 (0.74, 0.96) 0.010
Smoking, no vs yes 0.92 (0.83, 1.02) 0.12
Seropositivity, no vs yes
At start 1.27 (1.08, 1.51) 0.0052c
At 2 years 1.01 (0.87, 1.16) 0.0043d
At 4 years 0.80 (0.63, 1.02)
Co-morbidity, yes vs no 1.29 (0.995, 1.68) 0.054
Year of initiation
200409 vs 19992003 1.35 (1.18, 1.55) <0.0001
20102013 vs 19992003 2.05 (1.68, 2.50) <0.0001
bDMARD
Adalimumab vs ABA 0.73 (0.56, 0.93) 0.012
Certolizumab pegol
vs ABA
0.40 (0.18, 0.87) 0.020
Etanercept vs ABA 0.74 (0.56, 0.94) 0.015
Golimumab vs ABA 1.03 (0.72, 1.49) 0.85
Infliximab vs ABA 0.82 (0.64, 1.06) 0.14
Tocilizumab vs ABA 0.62 (0.46, 0.85) 0.0031
Shown are estimated hazard ratios (HRs), 95% Wald CIs and
associated P-values for all covariates based on a model not
accounting for multiple TCs per patient. For discrete or con-
tinuous covariates ratios are shown for a difference corre-
sponding approximately to the interquartile range. For
DAS28 and seropositivity, several HRs are shown to illustrate
their behaviour over time. aP-value for the effect of DAS28 in
the first year. bP-value for the change in the effect of DAS28
when going from <1 year to 51 year. cP-value for the effect
of seropositivity at start of treatment. dP-value for the change
in the effect of seropositivity with time since start of treatment.
Of the 2453 TCs, 1860 TCs [76%, including 1155 observed
discontinuations (62%)] were initiated in combination therapy
and 593 [including 390 observed discontinuations (66%)] in
monotherapy. bDMARDs: biologic DMARDs; ABA: abatacept.
FIG. 1 Retention of biologic DMARDs used in monother-
apy or in combination with synthetic DMARDs
KaplanMeier plot of unadjusted retention of biologic
DMARDs (bDMARDs) for initial mono- (grey) and com-
bination (black) therapy based on 3312 treatment courses
(P= 0.018, log-rank test, not accounting for multiple
treatment courses per patient). Small diagonal lines indi-
cate censored retention times. Treatment courses with
rituximab or immediate loss to follow-up were excluded.
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complete-case analyses especially with respect to our
main interest, the effect of type of therapy on bDMARD
retention and evolution of DAS28 (details not shown).
DAS28 response rates
All 1859 TCs with at least one follow-up visit around 12
months (in the time window of 915 months) after
bDMARD treatment initiation were used for the analysis
of DAS28 response rates. Of these TCs, 76% had com-
plete baseline covariate data and were used in a multiple
adjusted analysis. Remission and LDAS at 12 months
were less frequently achieved in monotherapy compared
with combination TCs: remission 32% vs 35%, LDAS 51%
vs 54%, respectively, but this did not reach statistical sig-
nificance [remission: unadjusted odds ratio (OR) 0.87
(95% CI 0.70, 1.10), multiple-adjusted (m.a.) OR 0.91
(95% CI 0.67, 1.23), LDAS: unadjusted OR 0.89 (95% CI
0.72, 1.10), m.a. OR 0.81 (95% CI 0.61, 1.09)]. After 24
months of treatment (in the time window 2127 months,
n= 797 TCs with complete covariate information), remis-
sion was numerically lower [m.a. OR 0.82 (95% CI 0.54,
1.23)] and LDAS was significantly lower in TCs started in
monotherapy compared with combination therapy [m.a.
OR 0.62 (95% CI 0.42, 0.92), P= 0.02)]. ORs were
very similar in analyses where TCs discontinued before
the follow-up visit at 12 or 24 months after the start of
treatment were imputed as non-responders (data not
shown).
Discussion
We found that bDMARDs were initially prescribed as
monotherapy in 27% of TCs (1446% depending on
bDMARD). In addition, in 13% (422% depending on
bDMARD) of TCs started in combination therapy, at
least one transient phase of monotherapy occurred.
Initial monotherapy with bDMARDs was more often pre-
scribed to older RA patients with kidney, lung or liver co-
morbidities, a lower BMI, longer disease duration, higher
number of previous bDMARDs and higher disease activ-
ity. Patients treated initially in monotherapy may, thus,
represent a subgroup of patients that is more difficult to
manage. We observed that bDMARDs are more effective
when started in combination with sDMARDs, both in
terms of clinical response and based on bDMARD reten-
tion. However, although statistically significant, the differ-
ences between the two groups were relatively modest.
Other factors seem to play a more important role, such
as the year of treatment initiation of the bDMARD or the
type of bDMARD, both for clinical response and drug
retention.
Studies based on different registries have observed that
bDMARDs are prescribed in monotherapy in up to one-
third of RA patients [310]. An observational study by
Soliman et al. [4] found that the use of aTNFs in mono-
therapy was associated with older age and longer disease
duration, higher number of prior bDMARDs, higher DAS28
and HAQ, and higher percentage of co-morbidities at
baseline. Taken together, these results and our data indi-
cate that the prevalence of bDMARD monotherapy is rela-
tively stable in different countries and that bDMARDs in
monotherapy are preferentially prescribed to patients with
more difficult disease management.
We observed that retention was decreased when the
bDMARD was started in monotherapy as compared with
combination therapy. It is likely that this difference is due
to a relative lack of efficacy rather than to adverse events.
Indeed, DAS28 response for initial monotherapies was
slightly but significantly decreased as compared with ini-
tial combination therapies. aTNFs were used in 3364
(80%) of the 4218 TCs and had, therefore, a large influ-
ence on our results. Soliman et al. [4] found that drug re-
tention is reduced when aTNFs are prescribed in
monotherapy as compared with in combination with
MTX. These data are also consistent with several clinical
trials showing that aTNFs are consistently more effica-
cious in combination with MTX than in monotherapy (re-
viewed in [13, 14]). Of note, these studies included either
MTX-naı¨ve patients or patients with inadequate response
to MTX. In contrast, the ADORE study [15] showed similar
clinical responses with etanercept alone and with
FIG. 2 Evolution of DAS28 in treatment courses with
bDMARDs in monotherapy or in combination with
sDMARDs
Smoothed unadjusted time course of DAS28 for initial
mono- (grey) and combination (black) therapy based on
4218 treatment courses (TCs) and 13 370 observations.
Smoothing was done using cubic splines. A total of 2926
TCs had one or more follow-up visits after start of biologic
treatment and 1292 contributed only with a baseline ob-
servation. The number of TCs still under observation is
listed above the time axis. Baseline, initial change and
longer-term slope indicate the different phases of the
DAS28 time course that were modelled in the longitudinal
mixed-effects analysis. The unadjusted difference in the
course of DAS28 over time between initial mono- and
combination therapy based on such a longitudinal mixed-
effects regression model was significant (P< 0.0001,
likelihood ratio test, accounting for multiple TCs per
patient).
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etanercept in combination with MTX in patients with active
disease despite MTX therapy. Another exception is based
on aTNF data of the RABBIT registry, where no significant
differences in remission rates between mono- and com-
bination therapy were found [5].
The efficacy of monotherapy with bDMARDs other than
aTNFs has also been investigated earlier. In a randomized
clinical trial the combination of rituximab and MTX, but not
rituximab alone, was superior to MTX, as assessed by the
number of patients achieving ACR50 response. Of note,
DAS28 changes, as well as the rate of good and moderate
EULAR responders, were superior in both the rituximab
alone and the rituximab combination group as compared
with MTX alone [16]. The results from a large cohort of
patients included in various European registries did not
find any difference between rituximab monotherapy and
the combination of rituximab and MTX regarding DAS28
response [17]. In the Accompany study, which included
both MTX-naı¨ve and patients previously treated with MTX
with active disease, the clinical response was similar when
abatacept was used in monotherapy or in combination
with MTX [18]. The efficacy of tocilizumab in monotherapy
was extensively studied in both MTX-naive patients and
MTX inadequate responders [1921]. The Act-Ray study
showed that in patients with active disease despite MTX
therapy, switching to tocilizumab monotherapy or adding
tocilizumab to MTX resulted mostly in comparable clinical
and radiological outcomes [2]. Tocilizumab in monother-
apy was superior to adalimumab in monotherapy in pa-
tients with inadequate response to MTX [22]. Taken
together, these results suggest that, according to their
mode of action, the effectiveness of bDMARDs in mono-
therapy may not significantly differ from that of bDMARDs
in combination with sDMARDs.
We found that the difference in DAS28 responses be-
tween monotherapy-initiated TCs and combination-ther-
apyinitiated TCs increased over time. The development
of anti-drug antibodies, in particular against monoclonal
anti-TNF antibodies, may explain this observation.
Progressive resistance to infliximab and adalimumab are
associated with the occurrence of anti-drug antibodies.
Importantly, co-therapy with MTX attenuates the develop-
ment of these antibodies [23, 24].
Year of TC initiation had a strong influence on bDMARD
retention. We arbitrarily divided the past 14 years into
three periods according to the availability of different
bDMARDs in Switzerland. Our results suggest that
rheumatologists are more likely to change the bDMARD
treatment in case of inadequate response if more treat-
ment choices are available.
Our study included a relatively large group of patients
followed longitudinally for several years recruited from
both academic and non-academic institutions (50%) and
smaller rheumatology practices (50%), which is represen-
tative of the general consultation situation in Switzerland.
It may, however, suffer from potential limitations inherent
in the analysis of observational data. Confounding by
indication may result in biased estimates for the initial
co-therapy effect. We counteracted this in our covariate-
adjusted analysis, but we cannot exclude the presence of
residual confounding by other unmeasured confounders.
One class of such potential unmeasured confounders are
characteristics of the previous TC. Apart from the number
of distinct biologics received prior to the current TC, we
have not considered any other information relating to
previous TCs. Missing data is another potential concern.
We lost 2229% of our data due to incomplete covariate
information. We have re-run some of our analyses based
on multiple imputation of missing covariates and obtained
fairly similar results to our complete-case analysis. We
prefer the complete-case analysis over the multiple imput-
ation approach for several reasons. A complete-case ana-
lysis is unbeatable in its simplicity and non-error-prone
implementation. Furthermore, after careful consideration
of the likely missingness mechanisms at work, we con-
cluded that a complete-case analysis is more likely to give
unbiased results than an analysis based on multiple im-
putation [2527]. Although our study included all the avail-
able bDMARDs, it was mostly driven by the most frequent
bDMARDs (adalimumab and etanercept), thus limiting the
possibility of examining the effectiveness of different
bDMARDs in monotherapy. International collaboration be-
tween registries will be useful for examining this question
in more detail for other bDMARDs. Some studies reported
that a substantial percentage of patients are non-adherent
to sDMARDs and that this is associated with decreased
treatment effectiveness [28, 29]. The extent of non-adher-
ence to sDMARD therapy by patients in our registry is not
known, but we would expect that the extent of non-ad-
herence does affect the comparison of monotherapy and
combination initiated bDMARDs.
Conclusion
Our study observed that just over a quarter of TCs with
bDMARDs were initiated as monotherapy, preferentially in
patients with more unfavourable disease characteristics
and co-morbidities. Overall, the effectiveness of
bDMARDs initiated as monotherapy was found to have
been slightly lower than that of bDMARDs initiated with
sDMARDs, but to an extent that seems only marginally
clinically relevant.
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